No Data
No Data
Express News | Surrozen Announces First Patient Dosed In Phase 1b Trial Of SZN-043 For Severe Alcohol-Associated Hepatitis
Express News | Surrozen : Szn-043 Clinical Trial Program in Severe Alcohol-Associated Hepatitis & Anticipate That Proof-of-Concept Data May Be Available in H1 2025
Express News | Surrozen Inc - Anticipate Potential Proof-of-Concept Data Available in First Half of 2025
Express News | Surrozen Initiates Dosing of First Patient in Phase 1B Clinical Trial of Szn-043 for Severe Alcohol-Associated Hepatitis
Surrozen Presents Data Demonstrating The Promise Of Antibody-Based Wnt Mimetics In Treating Cornea Endothelial Dystrophies And Dry Eye Disease At The ARVO Annual Meeting
In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the corneaSurrozen's antibody base
Express News | Surrozen Q1 EPS $(4.24) Beats $(4.25) Estimate
No Data